Overexpression of EphB4 participated in the cascade of SHP2/GAB1-MEK signals and activated c-myc, thus allowing HER2-positive BC cells to escape from lapatinib and limiting the overall drug response of lapatinib. This evidence concerns the gene ERBB2 and breast cancer.